Arbutus Biopharma Corp Cash Flow Conversion Efficiency
Arbutus Biopharma Corp cash flow conversion efficiency. Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has a cash flow conversion efficiency ratio of -0.023x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.02 Million) by net assets ($258.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arbutus Biopharma Corp (1998–2025)
Cash flow conversion efficiency of Arbutus Biopharma Corp from 1998 to 2025. This chart illustrates how Arbutus Biopharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Arbutus Biopharma Corp stock quote for real-time trading data and today's change.
Arbutus Biopharma Corp Cash Flow Conversion Ratio Explained
Arbutus Biopharma Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arbutus Biopharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arbutus Biopharma Corp ranked by their cash flow conversion efficiency. Also see ABUS market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seneca Foods Corp A
NASDAQ:SENEA
|
0.141x |
|
D-MARKET E.S.+T.SP.ADR/1B
F:8WZ
|
-3.858x |
|
Forum Energy Technologies Inc
NYSE:FET
|
0.043x |
|
ASRock Inc
TW:3515
|
-0.040x |
|
Compass Diversified Holdings
NYSE:CODI
|
0.049x |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
0.160x |
|
Beijing Shenzhou Aerospace Software Technology Co. Ltd. A
SHG:688562
|
N/A |
|
Zhejiang Qianjiang Motorcycle Co Ltd
SHE:000913
|
0.000x |
Annual Cash Flow Conversion Efficiency for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual cash flow conversion efficiency of Arbutus Biopharma Corp from 1998 to 2025. Review Arbutus Biopharma Corp free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $76.58 Million | $-39.64 Million | -0.518x | +22.28% |
| 2024-12-31 | $97.37 Million | $-64.85 Million | -0.666x | +17.83% |
| 2023-12-31 | $106.02 Million | $-85.94 Million | -0.811x | -213.75% |
| 2022-12-31 | $136.85 Million | $-35.36 Million | -0.258x | +35.18% |
| 2021-12-31 | $169.44 Million | $-67.53 Million | -0.399x | +21.00% |
| 2020-12-31 | $101.97 Million | $-51.44 Million | -0.504x | +48.32% |
| 2019-12-31 | $72.74 Million | $-71.01 Million | -0.976x | -187.85% |
| 2018-12-31 | $200.23 Million | $-67.90 Million | -0.339x | -27.34% |
| 2017-12-31 | $182.50 Million | $-48.60 Million | -0.266x | +6.61% |
| 2016-12-31 | $203.00 Million | $-57.88 Million | -0.285x | -185.06% |
| 2015-12-31 | $547.68 Million | $-54.78 Million | -0.100x | +29.13% |
| 2014-12-31 | $88.00 Million | $-12.42 Million | -0.141x | -23.99% |
| 2013-12-31 | $59.19 Million | $-6.74 Million | -0.114x | -114.00% |
| 2012-12-31 | $40.92 Million | $33.27 Million | 0.813x | +156.28% |
| 2011-12-31 | $5.21 Million | $-7.52 Million | -1.445x | -37.84% |
| 2010-12-31 | $10.73 Million | $-11.25 Million | -1.048x | -608.93% |
| 2009-12-31 | $35.44 Million | $-5.24 Million | -0.148x | +33.28% |
| 2008-12-31 | $38.29 Million | $-8.48 Million | -0.222x | -49.67% |
| 2007-12-31 | $18.37 Million | $-2.72 Million | -0.148x | +99.12% |
| 2006-12-31 | $155.53K | $-2.62 Million | -16.866x | -2240.30% |
| 2005-12-31 | $-18.49 Million | $-14.57 Million | 0.788x | -17.14% |
| 2004-12-31 | $-10.50 Million | $-9.98 Million | 0.951x | +253.00% |
| 2003-12-31 | $43.38 Million | $-26.96 Million | -0.622x | -55.24% |
| 2002-12-31 | $45.35 Million | $-18.16 Million | -0.400x | -146.08% |
| 2001-12-31 | $61.49 Million | $-10.00 Million | -0.163x | +41.51% |
| 2000-12-31 | $30.03 Million | $-8.35 Million | -0.278x | -9.37% |
| 1999-12-31 | $26.88 Million | $-6.84 Million | -0.254x | +52.39% |
| 1998-12-31 | $14.43 Million | $-7.71 Million | -0.534x | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more